Results 81 to 90 of about 65,998 (238)

Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Recent advances in cancer screening, diagnosis, and treatment have greatly improved survival rates among women with gynecologic cancers. More survivors now live long enough to experience treatment‐related menopause. Vasomotor symptoms, genitourinary syndrome of menopause, sexual dysfunction, sleep issues, and long‐term risks from estrogen ...
Agnaldo Lopes da Silva‐Filho, Suvarna Khadilkar, Hema Divakar, Chiara Benedetto, Andrea R. Genazzani, Diana Ramos, Elizabete Argale, Enrique Herrera, Martha Hickey   +8 more
wiley   +1 more source

Advances in Immunological Combination Therapy for Colorectal Cancer

iMetaMed, EarlyView.
Review the progress of combined immunotherapy for colorectal cancer. ABSTRACT Immune checkpoint inhibitors (ICIs) have been utilized extensively and shown to be therapeutically beneficial in the treatment of solid tumors in recent years. Nonetheless, considerable heterogeneity in Colorectal cancer (CRC) requires careful consideration.
Jiayue Wu, Rongbo Wen, Tianshuai Zhang, Fuao Cao, Xiaoming Zhu, Liqiang Hao, Wei Zhang, Guanyu Yu   +7 more
wiley   +1 more source

Enhanced peripheral blood mononuclear cell lipid metabolism drives poor immunotherapy response via ferroptotic stress‐induced T cell exhaustion in hepatocellular carcinoma

Interdisciplinary Medicine, EarlyView.
Integrated multi‐omics reveals that CD36‐mediated lipid overload in PBMCs drives T cell exhaustion via sub‐lethal ferroptotic stress and AKT suppression. This systemic metabolic signature serves as a robust predictor of immunotherapy response in HCC, suggesting that modulating lipid metabolism can rescue immune fitness.
Ying Zhu, Zhouyu Ning, Yong Deng, Changjing Huang, Hui Li, Yun Sun, Zhiqiang Meng   +6 more
wiley   +1 more source

Durable Cancer Control and Extended Long‐Term Survival Following Salvage Surgery for Squamous Cell Carcinoma of the Anal Canal: A Cohort Study

Journal of Surgical Oncology, EarlyView.
ABSTRACT Aim Salvage surgery is the standard‐of‐care for patients with squamous cell carcinoma of the anal canal (SCCa) who experience isolated locoregional failure after upfront chemoradiotherapy. While perioperative morbidity and short‐term survival outcomes have been described, long‐term outcomes of surgical salvage are unknown.
Paul Savage, David P. Cyr, Dan E. Schiller, Bernard J. Cummings, Alexandra M. Easson, Andrew J. Smith, Carol J. Swallow   +6 more
wiley   +1 more source

Diabetes Mellitus Induced by Nivolumab plus Regorafenib in a Patient with Esophageal Cancer

Journal of Cancer Research and Practice
Nivolumab is now preferred as first-line and second-line treatment for advanced esophageal cancer, while regorafenib improves survival in refractory gastroesophageal cancer.
Mei-Chen Lin, Li-Yuan Bai, Shih-Peng Yeh, Chang-Fang Chiu, Ming-Yu Lien   +4 more
doaj   +1 more source

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

JEADV Clinical Practice, EarlyView.
ABSTRACT Introduction Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto, Eleonora Bongiovanni, Veronica Arese, Michela Camilla Milanesio, Alessia Reali, Massimo Chiarpenello, Gianmauro Numico, Marcella Occelli   +7 more
wiley   +1 more source

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison

Frontiers in Oncology
BackgroundThe effectiveness of immune checkpoint inhibitors (ICIs) as adjuvant therapy for muscle-invasive urothelial carcinoma (MIUC) with high recurrence risk has been demonstrated.
Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii   +8 more
doaj   +1 more source

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo, Wei‐Chen Tai, Yen‐Hao Chen, Ming‐Chao Tsai, Jing‐Houng Wang, Sheng‐Nan Lu, Tsung‐Hui Hu, Chao‐Hung Hung, Chien‐Hung Chen, Yuan‐Hung Kuo   +9 more
wiley   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, EarlyView.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source